Shirsa Udgata
YOU?
Author Swipe
View article: Supplementary Video 1 from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids
Supplementary Video 1 from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids Open
Supplemental video 1 shows the method of spiking individual PDCO’s for mutation mixing studies.
View article: Supplemental Figure 2 from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids
Supplemental Figure 2 from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids Open
Supplemental Figure 2 shows leading-edge NAD(P)H and FAD normalized intensity graphs for PDCO’s with different mutation profiles, corresponding with main Fig. 4B.
View article: Supplemental Table 1 from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids
Supplemental Table 1 from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids Open
Supplemental Table 1 indicates the number of PDCOs assessed with WF ORI per experiment.
View article: Supplemental Table 2 from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids
Supplemental Table 2 from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids Open
Supplemental Table 2 shows the number of PDCOs and cells assessed with 2P ORI per condition.
View article: Supplemental Figure 3 from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids
Supplemental Figure 3 from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids Open
Supplemental Figure 3 shows receiver operating characteristic (ROC) curves with different variable combinations, corresponding with main Fig. 4D.
View article: Supplemental Analysis Pipeline from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids
Supplemental Analysis Pipeline from Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids Open
Supplemental Analysis pipeline contains the CellProfiler pipeline used to generate leading-edge data reported in the manuscript. Dependency: CellProfiler v4.0.7 Inputs: Widefield Autofluorescence images of patient derived cancer organoids …
View article: An automated image analysis pipeline for wide-field optical redox imaging of patient-derived cancer organoids
An automated image analysis pipeline for wide-field optical redox imaging of patient-derived cancer organoids Open
Wide-field optical redox imaging provides a fast and accessible method to monitor metabolic changes in cells and has recently been developed for drug screening in patient-derived cancer organoids (PDCOs). However, manual analysis of wide-f…
View article: Correction: Schmitz et al. The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies. Biomedicines 2025, 13, 1319
Correction: Schmitz et al. The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies. Biomedicines 2025, 13, 1319 Open
Correction [...]
View article: Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids
Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids Open
Patient-derived cancer organoids (PDCO) are a valuable model to recapitulate human disease in culture, with important implications for drug development. However, current methods for rapidly and reproducibly assessing PDCOs are limited. Lab…
View article: The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies
The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies Open
Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (MTOR) pathway hyperactivation is seen in a multitude of malignancies. Due to the importance of this pathway in numerous critical cellular functions, preclinical and cl…
View article: Cellpose as a reliable method for single-cell segmentation of autofluorescence microscopy images
Cellpose as a reliable method for single-cell segmentation of autofluorescence microscopy images Open
Autofluorescence microscopy uses intrinsic sources of molecular contrast to provide cellular-level information without extrinsic labels. However, traditional cell segmentation tools are often optimized for high signal-to-noise ratio (SNR) …
View article: Wide-field optical redox imaging with leading-edge detection for assessment of patient-derived cancer organoids
Wide-field optical redox imaging with leading-edge detection for assessment of patient-derived cancer organoids Open
Patient-derived cancer organoids (PDCOs) are a valuable model to recapitulate human disease in culture with important implications for drug development. However, current methods for assessing PDCOs are limited. Label-free imaging methods a…
View article: Cellpose as a reliable method for single-cell segmentation of autofluorescence microscopy images
Cellpose as a reliable method for single-cell segmentation of autofluorescence microscopy images Open
Autofluorescence microscopy uses intrinsic sources of molecular contrast to provide cellular-level information without extrinsic labels. However, traditional cell segmentation tools are often optimized for high signal-to-noise ratio (SNR) …
View article: Data from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement
Data from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement Open
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed too late for effective therapy. The classic strategy for early detection biomarker advancement consists of initial retrospective phases of discovery and validation with tissue samp…
View article: Supplementary Figure from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement
Supplementary Figure from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement Open
Supplementary Figure 1
View article: Supplementary Figure from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement
Supplementary Figure from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement Open
Supplementary Figure 1
View article: Data from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement
Data from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement Open
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed too late for effective therapy. The classic strategy for early detection biomarker advancement consists of initial retrospective phases of discovery and validation with tissue samp…
View article: Supplementary Table from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement
Supplementary Table from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement Open
Supplementary Table 1
View article: Supplementary Table from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement
Supplementary Table from THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement Open
Supplementary Table 1
View article: Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma Open
In addition, the paper's title has been corrected to read, 'THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma.
View article: THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma Open
Patients newly diagnosed with metastatic pancreatic ductal adenocarcinoma generally have poor survival, with heterogeneous rates of progression. Biomarkers that could predict progression and/or survival would help inform patients and provi…
View article: THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement
THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement Open
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed too late for effective therapy. The classic strategy for early detection biomarker advancement consists of initial retrospective phases of discovery and validation with tissue samp…